Life Care Medical Devices to Present at the 8th Annual LD Micro Main Event on December 2, 2015

NEW SMYRNA BEACH, Fla. and BRIGHTON, United Kingdom, Nov. 23, 2015 (GLOBE NEWSWIRE) -- Life Care Medical Devices Limited (“Life Care,” “LCMD” or the “Company”), a medical device company focused on the development, production and distribution of non-invasive and minimally-invasive technologies, today announced that it will present at the 8^th Annual LD Micro Main Event on Wednesday, December 2, 2015, at 4:30 p.m. Pacific Time at the Luxe Sunset Hotel in Los Angeles, California.

Richard J. Prati, Chief Executive Officer, will provide an update on the Company’s commercial plans for Life Care EMI (formerly the BioFusionary Bebe™), a non-invasive aesthetic and physiologic device which uses electromagnetic induction to generate and deliver focused energy to the collagen-rich dermis and subcutaneous tissues. Mr. Prati will also discuss the Company’s recent commercial launch of LapCap2^®, a proprietary device specifically designed to advance the standard of care for laparoscopic surgery by providing safe, rapid and repeatable access for minimally invasive abdominal procedures.

A live audio webcast of the presentation will be available by accessing Life Care’s IR Calendar in the Investors section of the Company's website (www.lcmd.com). The webcast replay will be available approximately two hours after the presentation and will be accessible for one month.

About LD Micro
LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The annual Main Event micro-cap conference was designed to highlight and showcase the next generation of great companies to private and institutional investors, as well as to analysts, bloggers, and the media. The firm also hosts the LD Micro Invitational. LD Micro is a non-registered investment advisor.

About Life Care Medical Devices Limited
Life Care Medical Devices (“Life Care”) is a company focused on the development, production and distribution of non-invasive and minimally-invasive technologies and products intended to reshape the treatment paradigm for medical procedures. The Company’s lead product, Life Care EMI, is a non-invasive system that uses electromagnetic induction (EMI) to generate focused energy. This energy passes through the skin surface and delivers localized, planar heat to the collagen-rich dermis and subcutaneous tissues. Life Care EMI recently received FDA clearance for generation of deep heat within tissues for the treatment of selected medical conditions. Life Care’s innovative product, LapCap2^®, is a proprietary device specifically designed to advance the standard of care for laparoscopic surgery by providing safe, rapid and repeatable access for minimally invasive abdominal procedures. Life Care is dedicated to improving surgery by working to ensure LapCap2 becomes the global standard for laparoscopic access. Life Care is also actively pursuing a robust growth strategy to expand its portfolio through the acquisition of synergistic products and technologies.

For more information, please visit www.lcmd.com and connect with the Company on Twitter, Facebook and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or LCMD’s prospects should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: LCMD ability to integrate the BioFusionary products into its current operations; LCMD’s dependence on third parties for its research and development, manufacturing and distribution functions; LCMD’s dependence on its license relationships; the risks and uncertainties associated with LCMD’s ability to manage its limited cash resources; obtaining additional financing to support LCMD’s operations; protecting the intellectual property developed by or licensed to LCMD in the transactions described above; and LCMD’s ability to build its operations to support its business strategy and promote its products. LCMD may not actually achieve the goals or plans described in its forward-looking statements.

Investor Relations
Jenene Thomas Communications, LLC
Jenene Thomas
Phone: [phone]
Email: [e-mail]

Media Contact
Razor Sharp PR
Ray Young
Phone: [phone]
[e-mail]